A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC

Immune checkpoint inhibitors (ICIs) have become a vital part of the therapeutic landscape for non‐small cell lung cancer (NSCLC) in recent years benefiting from their remarkable efficacy. However, ICIs are associated with potentially life‐threatening immune‐related adverse events (irAEs). This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Renwei, Kong, Daming, Chen, Rong, Guo, Yuchen, Jian, Weizhe, Han, Mengyi, Zhou, Tianyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381889/
https://www.ncbi.nlm.nih.gov/pubmed/35763678
http://dx.doi.org/10.1002/psp4.12834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381889/
https://www.ncbi.nlm.nih.gov/pubmed/35763678
http://dx.doi.org/10.1002/psp4.12834

Ejemplares similares